Coalition to Save Pure Files Proxy Documents With SEC, Urges Pure's Board to Set an Annual Meeting Date

The Coalition to Save Pure, a group of stockholders and director nominees that has nominated a slate of six individuals to replace the current board of directors of Pure Bioscience, Inc. PURE, today filed its preliminary proxy statement with the Securities and Exchange Commission. Pure owns the rights to silver dihydrogen citrate (SDC), an antibacterial, antiviral and antifungal technology.